

*To the Copenhagen Stock Exchange  
and the Press*

Release no. 21/2007

## **Long lasting immune response and survival to RAS vaccine**

*Summary: Follow-up RAS data presented at ASCO*

Professor Trond Buanes today gave a presentation titled "*RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival*" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicates that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of other proprietary cancer peptide vaccines, including GV1001 which is in phase III clinical trials.

Hørsholm, June 4, 2007

Jakob Schmidt  
Chief Executive Officer

### **Additional information:**

Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525

Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

**Note to editors:** *Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.*